Recombinant killed whole cell genome-reduced bacterial vaccine for AIBV
This innovative vaccine platform utilizes killed whole cell bacterial vaccines (KWC/GRB) to express pathogen subunits for broad protection. It leverages gram-negative autotransporter expression for cost-effective, scalable production, targeting avian infectious bronchitis virus (AIBV).
Overview
The recombinant killed whole cell genome-reduced bacterial vaccine (KWC/GRB) represents a cutting-edge platform designed to combat avian infectious bronchitis virus (AIBV). By leveraging the expression of pathogen subunits on genetically reduced bacteria (GRB), this approach utilizes Gram-negative autotransporter expression cassettes. This method is analogous to the successful influenza vaccines developed by the same team and is expected to provide broad protection against multiple AIBV serotypes. The cost-effective production and stability at 2-6°C for two years make it particularly suitable for widespread use in poultry.
Technical specifications
- Pathogen Subunit Expression: Utilizes monomeric or trimeric autotransporter (Hia) expression cassettes in synthesized plasmids.
- Cost-Effective Production: Constructs cost approximately $100 each, with a turnaround time of two weeks.
- Delivery Routes: Immunogenic via intramuscular (IM) and intraocular (IO) administration, with potential for oral (PO) administration.
- Scalable Manufacturing: Utilizes conventional bacterial vaccine production methods, suitable for existing global facilities using yeast lysate as feedstock.
- Stability: Stable at refrigeration temperatures (2-6°C) for up to two years.
Technology readiness level
The KWC/GRB vaccine platform is currently at Technology Readiness Level 4, having demonstrated proof of concept in laboratory settings with ongoing validation efforts. Future plans include further development and testing in poultry models, scaling up production, and conducting field trials with potential regulatory filings.
About University of Virginia
The University of Virginia is a comprehensive public research university with broad academic programs and a robust research enterprise. Integration with UVA Health enables clinical translation, large-scale trials, and data-driven care in an academic medical setting. A university-operated discovery park, North Fork—A UVA Discovery Park, co-locates companies with faculty and government partners, while participation in the Commonwealth Center for Advanced Manufacturing gives access to production-scale testbeds and joint industry projects. Research is supported by competitive federal funding, including NIH, NSF, DOE, and DoD. The Licensing & Ventures Group manages IP, licensing, and startup formation to speed commercialization.
delivered to your inbox.